• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Atrial fibrillation and chronic kidney disease: A bad combination.

作者信息

Kiuchi Márcio Galindo

机构信息

Department of Artificial Cardiac Stimulation and Electrophysiology, Cardiostim, Niterói, RJ, Brazil.

出版信息

Kidney Res Clin Pract. 2018 Jun;37(2):103-105. doi: 10.23876/j.krcp.2018.37.2.103. Epub 2018 Jun 30.

DOI:10.23876/j.krcp.2018.37.2.103
PMID:29971204
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6027811/
Abstract
摘要

相似文献

1
Atrial fibrillation and chronic kidney disease: A bad combination.心房颤动与慢性肾脏病：糟糕的组合。
Kidney Res Clin Pract. 2018 Jun;37(2):103-105. doi: 10.23876/j.krcp.2018.37.2.103. Epub 2018 Jun 30.
2
Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease: Practical Issues.心房颤动合并慢性肾脏病患者的抗凝治疗：实际问题。
Anatol J Cardiol. 2022 Dec;26(12):857-863. doi: 10.5152/AnatolJCardiol.2022.2426.
3
Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation.慢性肾脏病与心房颤动患者的口服抗凝治疗。
Dtsch Arztebl Int. 2018 Apr 27;115(17):287-294. doi: 10.3238/arztebl.2018.0287.
4
Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care.在英国初级保健中，新开始抗凝治疗心房颤动的老年慢性肾脏病患者的缺血性中风、出血和死亡率：一项基于人群的研究。
BMJ. 2018 Feb 14;360:k342. doi: 10.1136/bmj.k342.
5
Intersection of cardiovascular disease and kidney disease: atrial fibrillation.心血管疾病与肾脏疾病的交集：心房颤动。
Curr Opin Nephrol Hypertens. 2014 May;23(3):275-82. doi: 10.1097/01.mnh.0000444820.80249.56.
6
Atrial fibrillation and heart failure: a bad combination.心房颤动与心力衰竭：糟糕的组合。
Curr Opin Cardiol. 2015 Mar;30(2):161-167. doi: 10.1097/HCO.0000000000000144.
7
Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.利伐沙班与华法林用于非瓣膜性心房颤动且伴有严重肾脏疾病或正在接受血液透析的患者。
Am J Med. 2019 Sep;132(9):1078-1083. doi: 10.1016/j.amjmed.2019.04.013. Epub 2019 May 2.
8
The effect of concomitant chronic kidney disease on the recurrence of atrial fibrillation after catheter ablation: A protocol for systematic review and meta-analysis.合并慢性肾脏病对导管消融后心房颤动复发的影响：系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 May 21;100(20):e25903. doi: 10.1097/MD.0000000000025903.
9
Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk.心房颤动与慢性肾脏病：降低血栓栓塞风险的治疗性抗凝方案综述
Clin Cardiol. 2018 Oct;41(10):1395-1402. doi: 10.1002/clc.23085. Epub 2018 Oct 25.
10
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.阿哌沙班与华法林在伴有心房颤动和慢性肾脏病晚期的患者中的比较。
Circulation. 2020 Apr 28;141(17):1384-1392. doi: 10.1161/CIRCULATIONAHA.119.044059. Epub 2020 Mar 12.

引用本文的文献

1
An integrated bioinformatics approach for identification of key modulators and biomarkers involved in atrial fibrillation.一种用于识别参与心房颤动的关键调节因子和生物标志物的综合生物信息学方法。
J Cardiovasc Thorac Res. 2025 Jun 28;17(2):109-120. doi: 10.34172/jcvtr.025.33347. eCollection 2025 Jun.
2
Effect of heart failure and atrial fibrillation on cardiorespiratory fitness in hemodialysis patients.心力衰竭和心房颤动对血液透析患者心肺适能的影响。
Int Urol Nephrol. 2025 Mar;57(3):897-906. doi: 10.1007/s11255-024-04260-w. Epub 2024 Oct 28.
3
Atrial Fibrillation and Chronic Kidney Disease: Aetiology and Management.心房颤动与慢性肾脏病：病因与管理
Rev Cardiovasc Med. 2024 Apr 9;25(4):143. doi: 10.31083/j.rcm2504143. eCollection 2024 Apr.
4
Association between changes in renal function and clinical outcomes in anticoagulated atrial fibrillation patients with marginal renal function. A nationwide observational cohort study.肾功能边缘状态的抗凝心房颤动患者肾功能变化与临床结局之间的关联。一项全国性观察性队列研究。
Front Cardiovasc Med. 2024 Jun 6;11:1423336. doi: 10.3389/fcvm.2024.1423336. eCollection 2024.
5
Polypharmacy in atrial fibrillation: A prospective analysis of mortality and ischemic stroke using the Clinical Practice Research Datalink.心房颤动中的多重用药：使用临床实践研究数据链对死亡率和缺血性卒中进行的前瞻性分析。
J Arrhythm. 2023 Nov 27;40(1):47-56. doi: 10.1002/joa3.12961. eCollection 2024 Feb.
6
Association of Chronic Kidney Disease With Atrial Fibrillation in the General Adult Population: A Nationwide Population-Based Study.慢性肾脏病与普通成年人群心房颤动的相关性：一项全国范围内基于人群的研究。
J Am Heart Assoc. 2023 Apr 18;12(8):e028496. doi: 10.1161/JAHA.122.028496. Epub 2023 Apr 17.
7
Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease: Practical Issues.心房颤动合并慢性肾脏病患者的抗凝治疗：实际问题。
Anatol J Cardiol. 2022 Dec;26(12):857-863. doi: 10.5152/AnatolJCardiol.2022.2426.
8
Dialysis Mode and Associated Outcomes in Patients With End-Stage Renal Disease and Atrial Fibrillation: A 14-Year Nationwide Cohort Study.终末期肾病伴心房颤动患者的透析模式及相关结局：一项长达 14 年的全国性队列研究。
J Am Heart Assoc. 2021 Jun 15;10(12):e019596. doi: 10.1161/JAHA.120.019596. Epub 2021 Jun 2.
9
Cerebrovascular Disease and Cognition in Chronic Kidney Disease Patients.慢性肾脏病患者的脑血管疾病与认知
Front Cardiovasc Med. 2020 Jun 3;7:96. doi: 10.3389/fcvm.2020.00096. eCollection 2020.
10
Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease.影响心房颤动合并慢性肾脏病患者达比加群谷浓度的因素
High Blood Press Cardiovasc Prev. 2020 Apr;27(2):151-156. doi: 10.1007/s40292-020-00373-2. Epub 2020 Mar 25.

本文引用的文献

1
Concurrent renal dysfunction with ischemic heart disease is an important determinant for cardiac and cerebrovascular mortality in patients on chronic digoxin therapy for atrial fibrillation.在接受慢性地高辛治疗心房颤动的患者中，并发肾功能不全与缺血性心脏病是导致心脑血管死亡的重要决定因素。
Kidney Res Clin Pract. 2018 Jun;37(2):130-137. doi: 10.23876/j.krcp.2018.37.2.130. Epub 2018 Jun 30.
2
Catheter Ablation for Atrial Fibrillation with Heart Failure.心力衰竭合并心房颤动的导管消融治疗。
N Engl J Med. 2018 Feb 1;378(5):417-427. doi: 10.1056/NEJMoa1707855.
3
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
4
Recent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation: implications for therapies targeting the atrial autonomic nervous system.自主神经系统在房颤基质形成中的作用的最新见解：对靶向心房自主神经系统治疗的启示
Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4):850-9. doi: 10.1161/CIRCEP.112.972273.
5
Sympathetic nervous system: role in hypertension and in chronic kidney disease.交感神经系统：在高血压和慢性肾脏病中的作用。
Curr Opin Nephrol Hypertens. 2012 Jan;21(1):46-51. doi: 10.1097/MNH.0b013e32834db45d.
6
Patterns of baseline autonomic nerve activity and the development of pacing-induced sustained atrial fibrillation.基础自主神经活动模式与起搏诱导持续性心房颤动的发展。
Heart Rhythm. 2011 Apr;8(4):583-9. doi: 10.1016/j.hrthm.2010.11.040. Epub 2010 Nov 29.
7
Sympathetic neural activity in hypertension and related diseases.高血压及相关疾病中的交感神经活性。
Am J Hypertens. 2010 Oct;23(10):1052-60. doi: 10.1038/ajh.2010.154. Epub 2010 Jul 22.
8
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial.地高辛对舒张性心力衰竭发病率和死亡率的影响：洋地黄辅助研究组试验
Circulation. 2006 Aug 1;114(5):397-403. doi: 10.1161/CIRCULATIONAHA.106.628347. Epub 2006 Jul 24.
9
The effect of digoxin on mortality and morbidity in patients with heart failure.地高辛对心力衰竭患者死亡率和发病率的影响。
N Engl J Med. 1997 Feb 20;336(8):525-33. doi: 10.1056/NEJM199702203360801.
10
Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance.肥胖男性中胰岛素刺激骨骼肌血流的作用减弱。胰岛素抵抗的一种新机制。
J Clin Invest. 1990 Jun;85(6):1844-52. doi: 10.1172/JCI114644.